As of Jun 28
| +0.20 / +2.67%|
The 3 analysts offering 12-month price forecasts for DelMar Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 12.00. The median estimate represents a +55.84% increase from the last price of 7.70.
The current consensus among 3 polled investment analysts is to Buy stock in DelMar Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.